{"id":"cyclosporin-a-mycophenolate-mofetil-methotrexate","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Bone marrow suppression"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Hypertension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclosporin A blocks calcineurin-dependent T-cell activation by inhibiting IL-2 production. Mycophenolate mofetil selectively inhibits inosine monophosphate dehydrogenase, depleting guanosine nucleotides needed for lymphocyte proliferation. Methotrexate inhibits dihydrofolate reductase, further suppressing T and B cell proliferation. Together, these agents provide multi-target immunosuppression.","oneSentence":"This triple immunosuppressive combination inhibits T-cell activation and proliferation through calcineurin inhibition, inosine monophosphate dehydrogenase inhibition, and folate antagonism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:18.122Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Organ transplant rejection prevention"},{"name":"Autoimmune diseases (likely graft-versus-host disease or similar conditions)"}]},"trialDetails":[{"nctId":"NCT07124078","phase":"PHASE2","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2026-03-31","conditions":"Chronic Graft-versus-host-disease","enrollment":60},{"nctId":"NCT06816134","phase":"PHASE2","title":"Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-01-30","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Transplantation, Stem Cell","enrollment":48},{"nctId":"NCT07290803","phase":"","title":"This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-11-17","conditions":"Atopic Dermatitis","enrollment":1000},{"nctId":"NCT03842696","phase":"PHASE1, PHASE2","title":"Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-02-04","conditions":"Hematologic Diseases, Acute Leukemia in Remission, Chronic Myelogenous Leukemia - Chronic Phase","enrollment":43},{"nctId":"NCT05166967","phase":"PHASE3","title":"Targeted Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2022-01-01","conditions":"Haploidentical Hematopoietic Stem Cell Transplantation","enrollment":204},{"nctId":"NCT07352566","phase":"PHASE4","title":"Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-01-01","conditions":"Psoriasis, Atopic Dermatitis","enrollment":10},{"nctId":"NCT03320642","phase":"PHASE1","title":"GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2018-02-27","conditions":"Hematologic Malignancies","enrollment":84},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT06650553","phase":"NA","title":"Umbilical Cord Blood-Supported Haplo-HSCT for Aplastic Anemia Treatment Study","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2024-06-01","conditions":"Aplastic Anemias","enrollment":110},{"nctId":"NCT07108530","phase":"PHASE2","title":"Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-06","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT02342145","phase":"PHASE4","title":"Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major","status":"COMPLETED","sponsor":"Zhongming Zhang","startDate":"2015-04","conditions":"Beta-Thalassemia Major, Graft-versus-host Disease (GVHD)","enrollment":205},{"nctId":"NCT00544115","phase":"PHASE2","title":"Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2001-10-16","conditions":"Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia","enrollment":260},{"nctId":"NCT06869265","phase":"PHASE2","title":"Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-05-01","conditions":"Acute Myeloid Leukemia (AML), High Risk Acute Myeloid Leukemia(AML), Relapsed/Refractory Acute Myeloid Leukemia (AML)","enrollment":56},{"nctId":"NCT03828019","phase":"PHASE3","title":"Adalimumab vs. Conventional Immunosuppression for Uveitis Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2019-09-16","conditions":"Uveitis","enrollment":227},{"nctId":"NCT06674382","phase":"NA","title":"Haplo-HSCT for Myelofibrosis","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-01-01","conditions":"Myelofibrosis","enrollment":39},{"nctId":"NCT05998759","phase":"PHASE2","title":"Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia","status":"RECRUITING","sponsor":"Beijing Hospital","startDate":"2023-12-02","conditions":"Connective Tissue Diseases, Thrombocytopenia","enrollment":296},{"nctId":"NCT06949267","phase":"EARLY_PHASE1","title":"A Study of iMSC for the Prevention of Acute Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-06-01","conditions":"Acute Graft-versus-Host Disease","enrollment":56},{"nctId":"NCT06741813","phase":"NA","title":"Allo-HSCT vs ASCT in Adult T-LBL","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-01-01","conditions":"T Lymphoblastic Lymphoma","enrollment":230},{"nctId":"NCT04009525","phase":"PHASE4","title":"Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study","status":"COMPLETED","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2019-07-05","conditions":"Thalassemia Major","enrollment":823},{"nctId":"NCT02416388","phase":"PHASE2, PHASE3","title":"Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR","status":"RECRUITING","sponsor":"University Hospital, Angers","startDate":"2015-01","conditions":"Acute Myeloid Leukemia (AML)","enrollment":3100},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT05247203","phase":"PHASE1","title":"Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2022-05-11","conditions":"Systemic Lupus Erythematosus","enrollment":92},{"nctId":"NCT03871361","phase":"PHASE2","title":"Abatacept in Patients With Birdshot HLA A29 Uveitis","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2019-04-01","conditions":"Eye Diseases, Uveitis","enrollment":15},{"nctId":"NCT00574496","phase":"PHASE2","title":"Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-11-13","conditions":"Lymphoma","enrollment":25},{"nctId":"NCT00045305","phase":"PHASE2","title":"Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2006-10-24","conditions":"Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms","enrollment":17},{"nctId":"NCT00057954","phase":"PHASE2","title":"Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2005-11-09","conditions":"Lymphoma","enrollment":6},{"nctId":"NCT04082416","phase":"PHASE3","title":"Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2019-10-16","conditions":"Systemic Lupus Erythematosus","enrollment":335},{"nctId":"NCT04778618","phase":"PHASE2","title":"Individualized Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2020-12-01","conditions":"Haploidentical Hematopoietic Stem Cell Transplantation","enrollment":63},{"nctId":"NCT05634915","phase":"PHASE4","title":"Clinical Study of rATG Individualized Administration in Haploidentical Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-12-20","conditions":"Hematopoietic Stem Cell Transplantation, Acute Leukemia","enrollment":90},{"nctId":"NCT05303727","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-08","conditions":"Neuroblastoma","enrollment":64},{"nctId":"NCT02677181","phase":"PHASE4","title":"Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2016-01","conditions":"aGVHD","enrollment":100},{"nctId":"NCT05214066","phase":"PHASE2","title":"Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2019-02-01","conditions":"aGVHD, cGVHD","enrollment":60},{"nctId":"NCT05120687","phase":"","title":"Corticosteroid Combining Noncorticosteroid Systemic Immunomodulatory Therapy in VKH","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2021-10-15","conditions":"Vogt Koyanagi Harada Disease (VKH)","enrollment":200},{"nctId":"NCT04622956","phase":"PHASE1, PHASE2","title":"GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2020-10-07","conditions":"Graft Vs Host Disease, Hematopoietic Neoplasm","enrollment":47},{"nctId":"NCT04101578","phase":"","title":"Clinical Prognosis and Progression of Myasthenia Gravis Patients","status":"UNKNOWN","sponsor":"Da, Yuwei, M.D.","startDate":"2017-02-08","conditions":"Myasthenia Gravis","enrollment":2000},{"nctId":"NCT00919503","phase":"PHASE2","title":"Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2009-07-31","conditions":"Non-Neoplastic Hematologic and Lymphocytic Disorder","enrollment":98},{"nctId":"NCT04895423","phase":"PHASE4","title":"Evaluation of the Effectiveness and Safety of Immunosuppressive and Biological Therapy of Atopic Dermatitis in Childhood","status":"UNKNOWN","sponsor":"National Medical Research Center for Children's Health, Russian Federation","startDate":"2021-11-25","conditions":"Atopic Dermatitis","enrollment":160},{"nctId":"NCT00041288","phase":"PHASE2","title":"Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2001-10","conditions":"Leukemia, Lymphoma","enrollment":10},{"nctId":"NCT02487069","phase":"NA","title":"Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2015-06","conditions":"Acute Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":876},{"nctId":"NCT02885610","phase":"PHASE2","title":"Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2015-12","conditions":"Systemic Lupus Erythematosus","enrollment":249},{"nctId":"NCT03689465","phase":"PHASE4","title":"PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2018-10-29","conditions":"Hematopoietic Stem Cell Transplantation","enrollment":260},{"nctId":"NCT02042690","phase":"PHASE3","title":"Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients","status":"COMPLETED","sponsor":"Peking University","startDate":"2014-07","conditions":"Acute Lymphoblastic Leukemia","enrollment":131},{"nctId":"NCT00928018","phase":"PHASE3","title":"Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2009-06","conditions":"Non-hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":139},{"nctId":"NCT01883180","phase":"PHASE4","title":"ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2013-06","conditions":"Hematopoietic Stem Cell Transplantation, Antithymocyte Globulin, Viral Infection","enrollment":412},{"nctId":"NCT00245037","phase":"PHASE1, PHASE2","title":"Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2005-06","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":147},{"nctId":"NCT00281879","phase":"PHASE2","title":"Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2006-02","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":200},{"nctId":"NCT00281983","phase":"PHASE1, PHASE2","title":"Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2000-06","conditions":"Chronic Lymphocytic Leukemia","enrollment":100},{"nctId":"NCT00132691","phase":"PHASE4","title":"Multicenter Uveitis Steroid Treatment (MUST) Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2005-09","conditions":"Uveitis","enrollment":255},{"nctId":"NCT00775632","phase":"PHASE2","title":"Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2008-10","conditions":"Graft Versus Host Disease, Bone Marrow Transplantation","enrollment":78},{"nctId":"NCT02643589","phase":"NA","title":"Dose Study of Antithymocyteglobulin in Haploidentical Allogeneic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2013-06","conditions":"Hematopoietic Stem Cell Transplantation","enrollment":200},{"nctId":"NCT01834157","phase":"","title":"Improvement of Hand Dysfunction by Arthritis in Systemic Sclerosis","status":"UNKNOWN","sponsor":"Prof. Laszlo Czirjak","startDate":"2013-04","conditions":"Systemic Sclerosis, Arthritis","enrollment":160},{"nctId":"NCT00322101","phase":"PHASE3","title":"Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2006-01","conditions":"Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Adult Acute Myeloid Leukemia in Remission","enrollment":25},{"nctId":"NCT00972660","phase":"PHASE2","title":"Safety and Efficacy Study of Allogenic Mesenchymal Stem Cells to Treat Extensive Chronic Graft Versus Host Disease","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2009-09","conditions":"Graft Versus Host Disease","enrollment":52},{"nctId":"NCT01766375","phase":"PHASE3","title":"the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2012-08","conditions":"Acute Myeloid Leukemia","enrollment":200},{"nctId":"NCT01613963","phase":"","title":"Causes of Visual Loss in Retinal Disease","status":"UNKNOWN","sponsor":"Royal Surrey County Hospital NHS Foundation Trust","startDate":"2012-05","conditions":"Uveitis, Scleritis","enrollment":2000},{"nctId":"NCT00563589","phase":"NA","title":"Mycophenolate Mofetil for the Prophylaxis of Graft-versus-host Disease in High Risk Allogeneic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Hospital Authority, Hong Kong","startDate":"2003-08","conditions":"Graft vs Host Disease, Hematopoietic Stem Cell Transplantation","enrollment":30},{"nctId":"NCT00317785","phase":"PHASE2","title":"Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2005-05","conditions":"Leukemia, Lymphoma, Myelodysplastic Syndromes","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Cyclosporin A,mycophenolate mofetil,Methotrexate","genericName":"Cyclosporin A,mycophenolate mofetil,Methotrexate","companyName":"Guangxi Medical University","companyId":"guangxi-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple immunosuppressive combination inhibits T-cell activation and proliferation through calcineurin inhibition, inosine monophosphate dehydrogenase inhibition, and folate antagonism. Used for Organ transplant rejection prevention, Autoimmune diseases (likely graft-versus-host disease or similar conditions).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}